A human IgG-like bispecific antibody co-targeting epidermal growth factor receptor and the vascular endothelial growth factor receptor 2 for enhanced antitumor activity

Cancer Biology and Therapy

Volumn 17, Issue 2, 2016, Pages 139-150

  Chen, Zhiguo ^a,b   Xie, Wei ^a   Acheampong, Desmond Omane ^a   Xu, Menghuai ^a   He, Hua ^a   Yang, Mengqi ^a   Li, Chenchen ^a   Luo, Chen ^a   Wang, Min ^a   Zhang, Juan ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b CHANGSHA UNIVERSITY   (China)

Author keywords

Bispecific antibody; cancer therapy; co targeting; EGFR; VEGFR2

Indexed keywords

BISPECIFIC ANTIBODY; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; VASCULOTROPIN RECEPTOR; EGFR PROTEIN, HUMAN; KDR PROTEIN, HUMAN; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG SCREENING; HT-29 CELL LINE; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL, HUMANIZED; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; HT29 CELLS; HUMANS; MICE; MOLECULAR TARGETED THERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84961215184     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2015.1121344     Document Type: Article

References (43)

1. R.S.Herbst. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004; 59(2 Suppl):21-6; PMID:15142631; http://dx.doi.org/10.1016/j.ijrobp.2003.11.041
2. C.C.Lee, H.Y.Shiao, W.C.Wang, H.P.Hsieh. Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer. Expert Opin Investig Drugs 2014; 23(10):1333-48; PMID:24921970; http://dx.doi.org/10.1517/13543784
3. C.Chen, Y.Zhang, Y.Zhang, J.Li, S.W.Tsao, M.Y.Zhang. Superior antitumor activity of a novel antibody cotargeting human epidermal growth factor receptor 2 and type I insulin-like growth factor receptor, Mol Cancer Ther 2014 Jan; 13 (1):90-100; PMID:24227890; http://dx.doi.org/10.1158/1535-7163
4. H.Zhang, A.Berezov, Q.Wang, G.Zhang, J.Drebin, R.Murali, M.I.Greene. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 2007; 117(8):2051-8; PMID:17671639; http:dx.doi.org/10.1172/JCI32278
5. T.Luca, V.Barresi, G.Privitera, N.Musso, M.Caruso, D.F.Condorelli, S.Castorina. In vitro combined treatment with cetuximab and trastuzumab inhibits growth of colon cancer cells. Cell Prolif 2014; 47(5):435-47; PMID:25131935; http://dx.doi.org/10.1111/cpr.12125
6. Y.Yarden, J.Schlessinger Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor, Biochemistry 1987; 26 (5):1443-51; PMID:3494473
7. A.G.Batzer, D.Rotin, J.M.Ureña, E.Y.Skolnik, J.Schlessinger. Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol Cell Biol 1994 Aug; 14(8):5192-201; PMID:7518560
8. K.Oda, Y.Matsuoka, A.Funahashi, H.Kitano. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol 2005; 1:2005.0010; PMID:16729045; http:dx.doi.org/10.1038/msb4100014
9. A.K.Larsen, D.Ouaret, K.El Ouadrani, A.Petitprez. Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis. Pharmacol Ther 2011 Jul; 131(1):80-90; PMID:21439312; http://dx.doi.org/10.1016/j.pharmthera.2011.03.012
10. A.K.Olsson, A.Dimberg, J.Kreuger, L.Claesson-Welsh. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006 May; 7(5):359-71; PMID:16633338; http://dx.doi.org/10.1038/nrm1911
11. S.Guo, L.S.Colbert, M.Fuller, Y.Zhang, R.R.Gonzalez-Perez. Vascular endothelial growth factor receptor-2 in breast cancer. Biochim Biophys Acta 2010 Aug; 1806(1):108-21; PMID:20462514; http://dx.doi.org/10.1016/j.bbcan.2010.04.004
12. S.Tanno, Y.Ohsaki, K.Nakanishi, E.Toyoshima, K.Kikuchi. Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3. Lung Cancer 2004 Oct; 46(1):11-9; PMID:15364128; http://dx.doi.org/10.1016/j.lungcan.2004.03.006
13. Z.Zhang, K.G.Neiva, M.W.Lingen, L.M.Ellis, J.E.Nör. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ 2010 Mar; 17(3):499-512; PMID:19834490; http://dx.doi.org/10.1038/cdd.2009.152
14. L.Lamalice, F.Houle, G.Jourdan, J.Huot. Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38. Oncogene 2004 Jan 15; 23(2):434-45; PMID:14724572; http;//dx.doi.org/10.1038/sj.onc.1207034
15. M.Dougher, B.I.Terman. Autophosphorylation of VEGFR2 in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization. Oncogene 1999 Feb 25; 18(8):1619-27; PMID:10102632
16. L.Claesson-Welsh, M.Welsh. VEGFA and tumour angiogenesis. J Intern Med 2013 Feb; 273(2):114-27; PMID:23216836; http://dx.doi.org/10.1111/joim.12019
17. G.Des Guetz, B.Uzzan, P.Nicolas, M.Cucherat, J.F.Morere, R.Benamouzig, J.L.Breau, G.Y.Perret. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 2006 Jun 19; 94(12):1823-32; PMID:16773076
18. R.S.Herbst, A.Onn, A.Sandler. Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 2005 May 10; 23(14):3243-56; PMID:15886312; http://dx.doi.org/10.1200/JCO.2005.18.853
19. M.Markman. Antiangiogenic drugs in ovarian cancer. Expert Opin Pharmacother 2009 Oct; 10(14):2269-77; PMID:19671017; http://dx.doi.org/10.1517/14656560903120907
20. M.Kösem, I.Tuncer, C.Kotan, I.Ibiloğlu, M.Oztürk, M.K.Türkdoğan. Significance of VEGF and microvascular density in gastric carcinoma. Hepatogastroenterology 2009 Jul-Aug; 56(93):1236-40; PMID:19760978
21. M.Iida, T.M.Brand, M.M.Starr, E.J.Huppert, N.Luthar, H.Bahrar, J.P.Coan, H.E.Pearson, R.Salgia, D.L.Wheeler. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Mol Cancer 2014 Oct 24; 13:242; PMID:25344208; http://dx.doi.org/10.1186/1476-4598-13-242
22. T.Troiani, S.Napolitano, D.Vitagliano, F.Morgillo, A.Capasso, V.Sforza, A.Nappi, D.Ciardiello, F.Ciardiello, E.Martinelli. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. Clin Cancer Res 2014 Jul 15; 20(14):3775-86; PMID:24812410; http://dx.doi.org/10.1158/1078-0432.CCR-13-2181
23. M.A.Becker, T.Farzan, S.C.Harrington, J.W.Krempski, S.J.Weroha, X.Hou, K.R.Kalli, T.W.Wong, P.Haluska. Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth. Mol Cancer Ther 2013 Dec; 12(12):2909-16; PMID:24130056; http://dx.doi.org/10.1158/1535-7163.MCT-13-0547
24. W.Xie, D.Li, J.Zhang, Z.Li, D.O.Acheampong, Y.He, Y.Wang, Z.Chen, M.Wang. Generation and characterization of a novel human IgG1 antibody against vascular endothelial growth factor receptor 2. Cancer Immunol Immunother 2014 Sep; 63(9):877-88; PMID:24893856; http://dx.doi.org/10.1007/s00262-014-1560-9
25. M.E.McMellen, D.Wakeman, C.R.Erwin, J.Guo, B.W.Warner. Epidermal growth factor receptor signaling modulates chemokine (CXC) ligand 5 expression and is associated with villus angiogenesis after small bowel resection. Surgery 2010 Aug; 148(2):364-70; PMID:20471049; http://dx.doi.org/10.1016/j.surg.2010.03.020
26. Y.R.1.Cho, S.W.Choi, D.W.Seo. The in vitro antitumor activity of Siegesbeckia glabrescens against ovarian cancer through suppression of receptor tyrosine kinase expression and the signaling pathways. Oncol Rep 2013 Jul; 30(1):221-6; PMID:23673404; http://dx.doi.org/10.3892/or.2013.2468
27. J.R.Tonra, D.S.Deevi, E.Corcoran, H.Li, S.Wang, F.E.Carrick, D.J.Hicklin. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res 2006 Apr 1; 12(7 Pt 1):2197-207; PMID:16609035; http://dx.doi.org/10.1158/1078-0432.CCR-05-1682
28. G.N.Naumov, M.B.Nilsson, T.Cascone, A.Briggs, O.Straume, L.A.Akslen, E.Lifshits, L.A.Byers, L.Xu, H.K.Wu, Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 2009 May 15; 15(10):3484-94; PMID:19447865; http://dx.doi.org/10.1158/1078-0432.CCR-08-2904
29. K.D.Courtney, R.B.Corcoran, J.A.Engelman. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010 Feb 20; 28(6):1075-83; PMID:20085938; http://dx.doi.org/10.1200/JCO.2009.25.3641
30. S.Schubbert, K.Shannon, G.Bollag. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007 Apr; 7(4):295-308; PMID:17384584; http://dx.doi.org/10.1038/nrc2109
31. A.De Luca, M.R.Maiello, A.D'Alessio, M.Pergameno, N.Normanno. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 2012 Apr; 16 Suppl 2:S17-27; PMID:22443084; http://dx.doi.org/10.1517/14728222.2011.639361
32. C.A.Pratilas, D.B.Solit. Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res 2010 Jul 1; 16(13):3329-34; PMID:20472680; http://dx.doi.org/10.1158/1078-0432.CCR-09-3064
33. S.Chandarlapaty, A.Sawai, M.Scaltriti, V.Rodrik-Outmezguine, O.Grbovic-Huezo, V.Serra, P.K.Majumder, J.Baselga, N.Rosen. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011 Jan 18; 19(1):58-71; PMID:21215704; http://dx.doi.org/10.1016/j.ccr.2010.10.031
34. K.J.Gotink, H.M.Verheul. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action. Angiogenesis 2010 Mar; 13(1):1-14; PMID:20012482; http://dx.doi.org/10.1007/s10456-009-9160-6
35. M.V.Gelfand, N.Hagan, A.Tata, W.J.Oh, B.Lacoste, K.T.Kang, J.Kopycinska, J.Bischoff, J.H.Wang, C.Gu. Neuropilin-1 functions as a VEGFR2 co-receptor to guide developmental angiogenesis independent of ligand binding. Elife 2014 Sep 22; 3:e03720; PMID:25244320; http://dx.doi.org/10.7554/eLife.03720
36. T.Ohba, J.M.Cates, H.A.Cole, D.A.Slosky, H.Haro, T.Ando, H.S.Schwartz, J.G.Schoenecker. Autocrine VEGF/VEGFR1 signaling in a subpopulation of cells associates with aggressive osteosarcoma. Mol Cancer Res 2014 Aug; 12(8):1100-11; PMID:24759089, http://dx.doi.org/10.1158/1541-7786.MCR-14-0037
37. H.Xu, Y.Yu, D.Marciniak, A.K.Rishi, F.H.Sarkar, O.Kucuk, A.P.Majumdar. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells. Mol Cancer Ther 2005 Mar; 4(3):435-42; PMID:15767552; http:dx.doi.org/10.1158/1535-7163.MCT-04-0280
38. M.Tuna, A.Chavez-Reyes, A.M.Tari. HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells. Oncogene 2005 Feb 24; 24(9):1648-52; PMID:15674342; http;dx.doi.org/10.1038/sj.onc.1208345
39. T.Faltus, J.Yuan, B.Zimmer, A.Krämer, S.Loibl, M.Kaufmann, K.Strebhardt. Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. Neoplasia 2004 Nov-Dec; 6(6):786-95; PMID:15720805; http://dx.doi.org/10.1593/neo.04313
40. K.Liu, H.Chen, Q.You, H.Shi, Z.Wang. The siRNA cocktail targeting VEGF and HER2 inhibition on the proliferation and induced apoptosis of gastric cancer cell. Mol Cell Biochem 2014 Jan; 386(1-2):117-24; PMID:24158524; http://dx.doi.org/10.1007/s11010-013-1850-0
41. J.Folkman. Angiogenesis and apoptosis. Semin Cancer Biol 2003 Apr; 13(2):159-67; PMID:12654259; http://dx.doi.org/10.1016/S1044-579X(02)00133-5
42. Z.X.Xuan, L.N.Li, Q.Zhang, C.W.Xu, D.X.Yang, Y.Yuan, Y.H.An, S.S.Wang, X.W.Li, S.J.Yuan. Fully human VEGFR2 monoclonal antibody BC001 attenuates tumor angiogenesis and inhibits tumor growth. Int J Oncol 2014 Dec; 45(6):2411-20; PMID:25269419; http://dx.doi.org/10.3892/ijo.2014.2690
43. Y.H.Hsu, C.C.Wei, D.B.Shieh, C.H.Chan, M.S.Chang.Anti-IL-20 monoclonal antibody alleviates inflammation in oral cancer and suppresses tumor growth. Mol Cancer Res 2012 Nov; 10(11):1430-9; PMID:23002091; http://dx.doi.org/10.1158/1541-7786.MCR-12-0276